Arax Advisory Partners
ADPT icon

Arax Advisory Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Arax Advisory Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$164K Buy
5,676
+1,497
+36% +$36.8K ﹤0.01% 2455
2026
Q2 		$89.6K Buy
4,179
+4,028
+2,668% +$61.7K ﹤0.01% 2820
2026
Q1 		$2.1K Sell
151
-64
-30% -$1.02K ﹤0.01% 3097
2025
Q4 		$3.49K Sell
215
-3,941
-95% -$64.3K ﹤0.01% 3029
2025
Q3 		$62.2K Buy
+4,156
New +$50.6K ﹤0.01% 1729
2024
Q4 		– Sell
-97
Closed -$497 – 2419
2024
Q3 		$497 Hold
97
– – ﹤0.01% 2404
2024
Q2 		$352 Buy
+97
New +$308 ﹤0.01% 2376

Other funds holding ADPT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Arax Advisory Partners's ADPT Position: Q3 2026 in Review

Arax Advisory Partners increased its Adaptive Biotechnologies (ADPT) stake by 36% in Q3 2026, buying an estimated $36.8K and bringing the position to 5,676 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2455.

Arax Advisory Partners first reported a position in ADPT in Q2 2024 and has held it in 7 quarters since. 190 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Arax Advisory Partners held 5,676 shares of Adaptive Biotechnologies worth $164K as of Q3 2026.
  • Arax Advisory Partners bought 1,497 Adaptive Biotechnologies shares in Q3 2026, an estimated $36.8K.
  • Adaptive Biotechnologies made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #2455 holding.
  • Arax Advisory Partners first reported a position in Adaptive Biotechnologies in Q2 2024 and has held it in 7 quarters since.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.